Intrinsiqq
Apimeds Pharmaceuticals Inc. logo

Apimeds Pharmaceuticals Inc.

APUS

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$3M
EPS-$27.70
P/E-0.06
P/FCF-0.25
EV/EBITDA-0.57
FCF Yield–
Div. Yield–
Net Debt/FCF-0.9x
Apimeds Pharmaceuticals Inc. intrinsic value
52-Week Range
$0.64$4.75

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$23M

▼ -331.7% YoY

Op. Margin

–

ROIC

-13.25%

▲ +6310.0pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$12M

▼ -1124.6% YoY

Op. Cash Flow (TTM)

-$12M

▼ -1116.8% YoY

Net Debt

$10M

Cash & Equiv.

$18K

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with APUS

CompareIntrinsic value
PMHSPolomar Health Services Inc.
$0.15+45.00%30
TCRTAlaunos Therapeutics Inc.
$1.66+4.40%10
PULMPulmatrix Inc.
$1.28-10.21%40
OTLCOncotelic Therapeutics Inc.
$0.01+22.00%10
GTBPGT Biopharma, Inc.
$2.96-6.92%20
DAREDare Bioscience Inc.
$0.41-9.96%10
PTNPalatin Technologies, Inc.
$4.58-7.10%10
ONCOOnconetix Inc.
$2.89-8.54%50

Apimeds Pharmaceuticals (APUS) in two numbers

Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-0.06
Negative: a loss over the last twelve months. Price to free cash flow -0.25.
Financials

Questions about Apimeds Pharmaceuticals

Does Apimeds Pharmaceuticals (APUS) pay a dividend?

No. Apimeds Pharmaceuticals (APUS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 16 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in APUS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing APUS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.